Stocks/OKYO

Create a free account to see ACCE Scores

Sign up for free to unlock scores, score breakdowns, and stock analysis.

OKYO

↓ PDF (Pro)
OKYO Pharma Limited Ordinary Shares
HealthcareBiotechnologyUnited KingdomNASDAQ
$1.63
-2.98%today
MKT CAP
$90M
-1.2% · 1Y
Earnings History
-
-
-
Q3 '24
Q4 '24
Q1 '25
Analyst Targets
Current price
$1.63
Low
$7.00
Analyst Mean
$9.00
High
$13.00
3 analystsStrong Buy
Full Financials
Trailing P/E-
Forward P/E-
EV/EBITDA-9.4x
Price/Sales-
Dividend Yield-
Revenue Growth YoY-
Earnings Growth YoY-
Revenue Growth QoQ-
5y Revenue CAGR-
5y Earnings CAGR-
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
ROE-
Debt / Equity-
Free Cash Flow$-3,001,427
Insider Ownership30.4%
Institutional Ownership9.1%
Short % of Float0.64%
Days to Cover2.6d
1 Week+5.2%
1 Month-
3 Months-
6 Months-
YTD-
1 Year-
3 Years-
5 Years-
vs 50-day SMA-
vs 200-day SMA-
vs 52w High-
vs 52w Low-
Top Holders
HolderType% HeldValueΔ SharesAs of
Dauntless Investment Group, LLC institution1.16%$0.00B-80.53%2025-12-31
Renaissance Technologies, LLCinstitution0.34%$0.00B+234.95%2025-12-31
UBS Group AGinstitution0.15%$0.00B+2651.38%2026-03-31
Xtx Topco Ltdinstitution0.04%$0.00B+100.00%2025-12-31
Geode Capital Management, LLCinstitution0.03%$0.00B+0.00%2025-12-31
Cerity Partners LLCinstitution0.03%$0.00B+0.00%2025-12-31
Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fundfund0.03%$0.00B+0.00%2026-02-28
Morgan Stanleyinstitution0.00%$0.00B+100.00%2025-12-31
Osaic Holdings Inc.institution0.00%$0.00B+0.00%2025-12-31
EFG International AGinstitution0.00%$0.00B+100.00%2025-12-31
TickerCapScoreP/EFwd P/EEV/EBITDAROEGrossD/EDiv
PTGX
Protagonist Therapeutics Inc. Common Stock
$6.6B5------0.00%
CELC
Celcuity Inc. Common Stock
$6.7B5------0.00%
ACLX
Arcellx Inc. Common Stock
$6.7B5-------
KYMR
Kymera Therapeutics Inc. Common Stock
$7.0B-----27.1%0%5.230.00%
TECH
Bio-Techne Corp Common Stock
$7.1B3672.724.4----63.00%
HALO
Halozyme Therapeutics Inc. Common Stock
$7.9B7325.56.6----0.00%
Peers selected by sector + industry + nearest market cap. Best in column highlighted green, worst red.
Unlock Full Financials
Growth metrics, valuation multiples, and profitability ratios on Starter+.
Upgrade from $15/mo →
Recent Alerts
No alerts yet for OKYO.
Want deep analysis?
This stock isn't in the ACCE researched universe. Browse 300+ stocks with full thesis, scores, and financial models.
Browse ACCE Indices →
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.